Skin Biopsy Denied by Insurance? How to Appeal

Skin biopsies are among the most common dermatological procedures — essential for diagnosing skin cancer, autoimmune skin disease, inflammatory conditions, and infections. Yet insurance companies regularly deny skin biopsies through claim edits, coding disputes, and cost-sharing disagreements. This guide explains the most common biopsy denial scenarios and how to appeal each one.

Why Skin Biopsies Are Denied

Diagnostic vs. confirmatory coding disputes: Insurers sometimes argue that a biopsy was "confirmatory" (verifying a known diagnosis) rather than "diagnostic" (establishing an unknown diagnosis) and deny it on that basis — even when the clinical purpose was clearly diagnostic.

Multiple lesion billing disputes: Biopsying multiple lesions in a single visit generates multiple biopsy charges. Insurers may deny secondary biopsies as duplicate claims or apply global period bundling rules incorrectly.

Pathology cost-sharing: The biopsy procedure and the pathology interpretation are separate charges from separate providers (dermatologist and pathologist). Patients may face unexpected cost-sharing on the pathology interpretation, particularly if the pathologist is OON.

Reflex laboratory disputes: After biopsy, dermatopathologists may order reflex tests — immunofluorescence, immunohistochemistry, molecular testing (FISH for melanoma, PCR for lymphoma). These may be denied as additional procedures.

Cosmetic diagnosis code applied: If the billing code (ICD-10) describes a condition that is typically cosmetic, the biopsy may be denied even when performed for diagnostic purposes.

Diagnostic vs. Confirmatory: The Core Argument

A skin biopsy is diagnostic when it is performed to:

• Establish a new diagnosis in an unknown or uncertain lesion
• Rule out malignancy in a clinically concerning lesion
• Distinguish between two or more possible diagnoses
• Confirm a condition when the clinical diagnosis is uncertain

A biopsy is NOT "confirmatory" just because your dermatologist had a strong clinical suspicion of the diagnosis. Standard of care in dermatology requires tissue confirmation of:

• Any lesion suspicious for malignancy (basal cell, squamous cell, or melanoma)
• Inflammatory dermatoses where treatment depends on specific histopathologic findings
• Bullous disorders requiring direct immunofluorescence
• Connective tissue diseases (lupus, dermatomyositis) with cutaneous involvement

Your appeal should argue that:

• Clinical diagnosis alone is insufficient for conditions with serious treatment implications
• Histopathologic confirmation changes management (triggers sentinel lymph node biopsy for melanoma, guides biologic selection for inflammatory conditions)
• The standard of care requires tissue diagnosis, and denial is a departure from evidence-based medicine

Multiple Lesion Billing: Separate Sites on Same Day

When multiple lesions are biopsied in a single visit, CPT coding rules apply:

• CPT 11102: Tangential biopsy of skin; single lesion
• CPT 11103: Tangential biopsy; each separate/additional lesion (add-on code)
• CPT 11104: Punch biopsy of skin; single lesion
• CPT 11105: Punch biopsy; each separate/additional lesion (add-on code)
• CPT 11106: Incisional biopsy; single lesion
• CPT 11107: Incisional biopsy; each separate/additional lesion (add-on code)

Add-on codes (11103, 11105, 11107) are legitimate codes for additional biopsies performed in the same session at separate anatomic sites. They cannot be denied as duplicate claims. If your insurer denies add-on codes, cite CPT coding guidelines directly.

Document medical necessity for each lesion biopsied separately in the clinical note — why each lesion was clinically concerning and required histopathologic evaluation.

Pathology Cost-Sharing Disputes

The pathologist who reads your biopsy slides is often a separate provider from your dermatologist, working out of a reference laboratory. If that pathologist is OON:

• The No Surprises Act requires that OON lab/pathology providers in in-network facilities be reimbursed at in-network rates for non-emergency situations where you had no choice of provider
• Request a detailed EOB showing how the pathology charge was processed
• Appeal any OON pathology balance billing, citing that you had no meaningful ability to choose the pathologist

Reflex Testing After Biopsy

When a dermatopathologist orders additional testing on the biopsy specimen:

• Immunofluorescence: Standard for bullous disorders (pemphigus, BP, DH). Document the specific diagnostic question requiring IF.
• Immunohistochemistry (IHC): For melanoma typing, lymphoma workup, or distinguishing poorly differentiated tumors. Document the diagnostic rationale.
• FISH or molecular testing: For ambiguous melanocytic lesions, cutaneous lymphoma, or BRAF/NRAS testing for melanoma management.

If reflex tests are denied, appeal with documentation of the specific diagnostic question each test addresses and the treatment implications of the result.

ICD-10 Coding: Avoiding Cosmetic Trap Codes

Ensure your biopsy is billed with the appropriate diagnosis code reflecting the clinical concern:

• Use "neoplasm of uncertain behavior" or "suspicious lesion" codes when malignancy is being ruled out, rather than the final benign diagnosis
• For inflammatory dermatoses, use the specific condition code, not a vague "skin lesion" code
• For pigmented lesions: melanocytic nevi with concerning features have specific codes (D22.x) that carry diagnostic weight

Fight Back With ClaimBack

ClaimBack's biopsy appeal tools address diagnostic vs. confirmatory arguments, multiple lesion coding disputes, pathology cost-sharing, and reflex laboratory denials.

Start your free appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied